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Background: Hematopoietic evaluation of the patients after Hematopoietic stem cell transplantation (HSCT) is very
important. Erythroblast macrophage protein (Emp) is a key protein with function in normal differentiation of
erythroid cells and macrophages. Emp expression correlates with erythroblastic island formation, a process widely
believed to be associated with hematopoiesis in bone marrow. We aimed to investigate the hematopoietic
function of bone marrow from 46 HSCT patients and 16 inpatients with severe anemia applied to the treatment of
EPO by measuring Emp expression level.
Methods: Emp mRNA and protein expression levels in mononuclear cells of bone marrow and peripheral blood
samples were detected by RT-PCR and Western blotting method respectively.
Results: While hematopoiesis occurs in bone marrow, Emp expression level was elevated and more erythroblastic
islands were found , and Emp is upregulated in bone marrow in response to erythropoietin (EPO) treatment.
Conclusions: Emp expression correlates with erythroblastic island formation and has an important function for
bone marrow hematopoiesis. Emp could be a potential biomarker for hematopoietic evaluation of HSCT patients.
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Erythroblastic islandBackground
The erythroblastic island is a distinct anatomic unit
which consists of a central macrophage surrounded by
erythroid cells. These islands are present at various
stages of differentiation in the fetal liver and the adult
bone marrow, and have a key role in erythroid cell
proliferation and differentiation [1-4]. Gregory and Eaves
found that the erythroid cells differentiated through
morphologically defined stages of erythroid progenitors,
proerythroblasts, basophilic erythroblasts, polychromato-
philic erythroblasts, and orthochromatophilic erythroblasts
[5,6]. The orthochromatophilic erythroblasts then under-
went enucleation by extruding their nucleus and became
reticulocytes, further expelling all organelles and detaching
from their microenvironment to form mature circulating* Correspondence: xhhLh99@gmail.com
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reproduction in any medium, provided the orerythrocytes. Over the course of erythroid differentiation,
erythroblasts displayed a gradual decrease in cell size and
an increase in hemoglobin concentration [7]. The major
changes of erythroid cells occurred in erythroblastic
island, which correlate with the hematopoiesis of bone mar-
row. Despite recent advances, the mechanism of erythro-
blast maturation remains poorly understood. Previous
reports showed that within erythroblastic islands, both
erythroblast-macrophage and erythroblast-erythroblast
maturation occurred by extensive interactions [1,2,8-12].
Interestingly, only a few molecules have been definitively
shown to enhance the formation of erythroblastic islands.
The adhesive interaction involved α4β1 integrin and
vascular cell adhesion molecule-1 (VCAM-1) were first
identified in erythroblasts and macrophages, respect-
ively [13]. Recently, the role of ICAM-4 in erythroblastic
island formation has been clearly documented by gene
targeting in-vivo studies [14,15]. Emp was initiallyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics, HSCT type, underlying
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interactions during erythroid differentiation [1,2,8,9].
More recently, it was thought that Emp had an import-
ant role in erythroblastic island formation [8,16,17].
Using a transplant combination from Emp null fetal
liver cells to lethally irradiated wild-type sibling mice,
Soniet al. found that loss of Emp function in erythroid
cells resulted in impaired proliferation and terminal
differentiation[18]. These findings suggest that Emp
protein might be a potential molecular marker for
hematopoietic evaluation.
Hematopoietic stem cell transplantation (HSCT) is the
transplantation of stem cells derived from the bone mar-
row or blood [19]. Stem cell transplantation is a medical
procedure used in the fields of hematology and oncol-
ogy. Increase in the number of erythroblastic islands in
bone marrow always suggests a successful HSCT. How-
ever, no clinical correlation between Emp levels and
hematopoiesis has been established. In this study, we
evaluated hematopoietic function of bone marrow in
HSCT patients through the change of Emp expression
before and after HSCT. Based on our data, we suggest
that Emp is a potential biomarker for hematopoietic
evaluation of HSCT patients.
Methods
Patient characteristics of HSCT
The use of human cord blood and peripheral blood was
approved by Medical Ethical Committee of the Tongji
Medical College. Approval was granted in accordance
with Chinese legislations, and written informed consent
was obtained from all participants, in accordance with
the guidelines of the Chinese Ministry of Health. HSCT
recipients at the HSCT program of the Hematology and
Hemotherapy Discipline at Tongji Medical College,
Huazhong University of Science and Technology were
prospectively enrolled in this trial. Forty-six patients,
HSCT recipients from September 2008 to December
2009, were eligible for the study. Thirty-one patients
underwent allogeneic HSCTs, and 15 patients received
autologous HSCTs. In the allogeneic HSCT group, all
patients received HSCTs from a human leukocyte anti-
gen (HLA) of identical donor, and no patient received a
T-cell depleted HSCT. Demographic details for all 46
patients are shown in Table 1.
Peripheral blood and bone marrow were taken from
HSCT recipients at the point of 30, 90, and 180 days,
respectively. Before HSCT, all patient samples of periph-
eral blood and bone marrow were acted as the second
control group, and that 10 donors constituted the first
control group. Samples were processed for peripheral
blood and bone marrow smears, and isolation of mono-
nuclear cells.Isolation of mononuclear cells in peripheral blood and
bone marrow
Heparinized (10 IU/mL) peripheral blood and bone
marrow was layered on a Ficoll-Hypaque discontinuous
gradient system (Sigma) and centrifuged at 1200 × g for
30 min. The mononuclear cells at the interface of
plasma and Ficoll-Hypaque were collected and re-
suspended in serum-free dulbecco’s modified eagle
medium (DMEM). Then the quantity (A) of mono-
nuclear cells were detected by the blood cell analyzer
(Beckman Coulter), and their smears were examined by
Wright/Giemsa staining (Maker Biotechnology Co.,
China) for the erythroblastic cell ratio (B%) of mono-
nuclear cells. The erythroblastic cell of number was cal-
culated using the equation: erythroblastic cells (× 109/L) =
A(× 109/L) × B%Morphology
The morphology of peripheral blood and bone marrow
cells was examined by Wright/Giemsa staining. In
addition to using blood cell analyzer, cells were directly







Mean 46.3 ± 2.3
Bone
marrow
Mean value in 12 inpatients with severe
anemia
BMHD Low or extremely low
MMCs 4.7 ± 1.2 × 109/L




The Emp strip was invisible
BMHD, Bone marrow hyperplastic degree; Hb,Hemoglobin; MERm, Mean
erythroblastic cells of ratio in mononuclear cells; MMCs,mean
mononuclear cells.
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tration (10 μL blood or bone marrow) and stained with
Wright/Giemsa solution. The morphology of blood
cells was observed under microsope and at least 200
blood cells with nucleus were counted to determine the
ratio of erythroblastic cell in peripheral blood, or the
hyperplastic degree in bone marrow.Semi-quantitative RT-PCR
Mononuclear cells in bone marrow and peripheral blood
samples were adjusted to the same quantity (1 × 106 cells
in PBS). Total RNA was extracted from the cells and
single strand cDNA synthesis was performed by using
Blood RNA extraction kit (QIAGEN, Hilden, Germany)
and moloney murine leukemia virus-reverse transcrip-
tion kit (SuperSciptII, Life Technologies, Inc.) according
to the manufacturer’s directions. PCR primers used for







The first control 5.7 ± 1.3 1.1 ± 0.4 2.7 ± 1.5 1.4 ± 0.5
The second control 2.1 ± 0.7 6 ± 1.2 1.7 ± 0.6 10.3 ± 1.7
30 days after HSCT 2.5 ± 1.0a 13.6 ± 1.6a 1.5 ± 0.4 17.8 ± 1.9a
90 days after HSCT 3.2 ± 1.2a 15.4 ± 1.8a 2.2 ± 0.7 19.7 ± 1.4a
180 days after HSCT 3.0 ± 1.1a 14.2 ± 1.5a 2.1 ± 0.8 18.5 ± 1.6a
aP < 0.05, vs. the first control group.
bP < 0.05, vs. the second control group.
BMHD, Bone marrow hyperplastic degree; MERm, mean erythroblastic cells of ratio
cells; MIQAS, Mean islands quantity in a smear; MMCs, mean mononuclear cells; MWsense 5’-ACCCGACCCTCAAGGTGCCC-3’, antisense
5’-GTGGCCG TCTCACGCCTCTC-3’; β-actin5’-TTC
CTGGGCATGGAGTCCT-3’, antisense 5’-TGATCTT
CATTGTGCTGGGTG-3’. The gene expression levels
were normalized by β-actin.Western blot
Cells were lysed with lysis buffer (20 mMTris–HCl
pH 7.8, 1 mM EDTA, 50 mM sodium chloride, and 0.5%
NP-40), and protein concentration was determined by
BCA assay kit (Pierce, USA). Western blot analysis was
carried out as directions of manufacturer (Cell signaling
Biotech). Antibodies against human Emp (Abcam plc.
USA. ab65239) and β-actin (Cell signaling Biotech,
USA) were used. Results were visualized with horserad-
ish peroxidase-conjugated secondary antibodies (Sigma,
USA; 1:1000) and enhanced chemiluminescence.EPO treatment
Use of erythropoietin (EPO) hormone as an anti-
apoptotic permitted survival of erythroid progenitors
from erythrocyte colony-forming unit (CFU-E) through
early proerythroblast stages of differentiation [20]. A
total of 16 inpatients with severe anemia were applied to
the treatment of EPO (rhu EPO, 75 u per kg, 3 times
weekly, subcutaneous). Pre- and post-EPO treatment
bone marrow samples were obtained for morphology
and Emp expression analysis. There were six women and
10 men among 16 inpatients, and their mean age was
33 years. The mean hemoglobin level in 16 inpatients
was 46.3 ± 2.3 g/L before EPO treatment. Erythroblastic
islands were not visible in their bone marrow. The inpa-
tients characteristics before EPO treatment are shown in
Table 2.Statistical analysis
Statistical analysis between groups was performed using
Student t-test. Results were considered statistically sig-
nificant if Pvalues were <0.05.Bone marrow
) BMHD MIQAS MMCs
(×109/L)
MERm (%)
Activity 21.4 ± 4.5 12.8 ± 2.5 48 ± 4.3
Low or extremely low 3.2 ± 1.4a 5.3 ± 1.4a 16.7 ± 1.6a
Activity 43.3 ± 4.1a,b 6.6 ± 1.7a 23.5 ± 1.2a
More activity 46.2 ± 3.6a,b 10.4 ± 1.5a 31.2 ± 1.8a
Activity 44.7 ± 4.2a,b 8.8 ± 1.2a 33.4 ± 1.1a
in mononuclear cells; MERw, Mean erythroblastic cells of ratio in white blood
BCs,Mean white blood cells.
Figure 1 The hyperplastic degree and morphology of erythroblastic islands in bone marrow. (A) The bone marrow hyperplastic degree.
Extremely low (a), low (b), active (c), more active (d). The images were taken under 100 ×magnification. (B) Morphology of bone marrow
erythroblastic islands was shown under 100× (e), 400× (f), and 1,000 ×magnification (g). The larger arrow pointed to the macrophage and the
smaller ones indicated erythroblasts.
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Analysis of morphology
To analyze the hematopoietic function of bone marrow
in different groups, morphology analysis was conducted
in all samples.In the bone marrow donor group, theFigure 2 Emp expression levels in peripheral blood and bone marrow
(B)Emp mRNA levels in peripheral blood, bone marrow and Emp protein-p
in peripheral blood and bone marrow from the bone marrow donor group
are representative of three independent experiments. n = 3. *P < 0.05.MWBCs (Mean White Blood Cells) is 5.7 ± 1.3 × 109/L
and the MMCs (Mean Mononuclear Cells) is 2.7 ± 1.5 ×
109/L in peripheral blood. The MWBCs and MMCs in
peripheral blood from inpatients pre- and post-HSCT
were lower than that in the peripheral blood from bone. (A)Emp protein levels in bone marrow in pre- and post-HSCT groups.
ositive bone marrow. (C) The mean gray-scale ratio of Emp to β-actin
, pre-HSCT group and day 30, 90, or 180 post-HSCT groups. These data
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age of erythroblastic cells in white blood cells) and the
MERm (the percentage of erythroblastic cells in mono-
nuclear cells) were lower in peripheral blood from the
bone marrow donor group than that in peripheral blood
from inpatients pre- and post-HSCT (Table 3). The
morphological characteristics of bone marrow were
described by the bone marrow hyperplastic degree
(BMHD) and number of erythroblastic islands. The bone
marrow hyperplastic activity was examined in the donor
group, pre-HSCT, and post-HSCT groups. The BMHD
was low or extremely low in the pre-HSCT group.
Ninety days after HSCT, it showed an elevation in
hematopoietic activity (Table 3, Figure 1A). The MIQASs
(Mean Islands Quantity In a Smear) of bone marrow
erythroblastic islands (Table 3, Figure 1B) in the groups
were as follows: the donor group (21.4 ± 4.5), the pre-
HSCT group (3.2 ± 1.4), 30 days after HSCT (43.3 ± 4.1),
90 days after HSCT (46.2 ± 3.6), and 180 days after HSCT
(44.7 ± 4.2). The MIQAS in the donor group was higher
than that in the pre-HSCT group, but was less than that in
post-HSCT groups. However, The MMCs and MERm inFigure 3 Emp expression after EPO treatment in bone marrow. (A). Th
under 100× (a), 400× (b), and 1,000 × (c) magnification. The larger arrow pointed
mean gray-scale ratio of Emp to β-actin protein (MGREAp) in groups without EP
representative of three independent experiments. n= 3. *P< 0.05.the bone marrow from bone marrow donor group were
higher than that in the bone marrow from the pre- and
post-HSCT groups (Table 3).
The Emp expression
Emp protein and mRNA expressions were detected in
mononuclear cells from peripheral blood and bone
marrow. Emp protein was not detected in peripheral
blood pre-HSCT and post-HSCT groups. Emp protein
was undetectable in bone marrow in pre-HSCT group,
but was detected in post-HSCT group, and there is no
difference between day 30, 90, and 180 post- HSCT
groups (Figure 2A). Emp mRNA level was higher in
Emp protein-positive bone marrow than that in Emp
protein-negative bone marrow (P < 0.05) (Figure 2B).
Furthermore, Emp mRNA levels in mononuclear cells
from peripheral blood and bone marrow were signifi-
cantly increased after HSCT (P < 0.05) (Figure 2C).
Analysis of EPO treatment
In order to explore the correlation of Emp and erythro-
blastic island formation in bone marrow in patients withe bone marrow island in one of 16 patients treated with EPO was shown
to the macrophage and the smaller ones indicated erythroblasts. (B) The
O treatment, or with EPO treatment for 30 and 90 days. These data are
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the erythroblastic islands were barely found in bone
marrow smears. After EPO treatment, the number of
erythroblastic islands was dramatically increased in the
bone marrow smear. (Table 2, Figure 3A). The Emp pro-
tein was undetectable in mononuclear cells from bone
marrow in patients not treated with EPO. However, after
EPO treatment the Emp protein was significantly in-
creased in mononuclear cells from bone marrow, in ac-
cordance with enhanced island formation (Figure 3B).
Discussion
HSCT is a potentially curative therapy for a variety of
hematological disorders and cancers of the blood or
bone marrow, such as multiple myeloma or leukemia.
Hematopoietic evaluation of the patients after HSCT is
very important.
In humans, the functional unit for definitive erythro-
poiesis is the erythroblastic island, a multicellular struc-
ture composed of a central macrophage surrounded by
developing erythroblasts. Erythroblast-macrophage in-
teractions play a central role in the terminal matur-
ation of erythroblasts [1,2,9]. Reconstitution and
increase of erythroblastic islands in bone marrow was
usually used as a marker for successful HSCT.
Erythroblast-macrophage protein (Emp) was initially
identified as a mediator of erythroblast-macrophage
interactions during erythroid differentiation. The Emp
protein [1,2,8,16,18] plays an important role in normal
maturation process of erythroblastic cells in erythro-
blastic islands in bone marrow. More recent studies
have shown that targeted disruption of Emp leads to ab-
normal erythropoiesis. Unfortunately, the involvement of
Emp in HSCT remains uncertain. In this report, we showed
that Emp protein levels were correlated with erythroblastic
island formation in bone marrow.
Emp was expressed in a variety of hematopoietic (and
indeed many non-hematopoietic) cells, including eryth-
roblasts and macrophages [21]. However, Emp expres-
sion increased in erythroblasts when hematopoiesis took
place in bone marrow (Table 3). Interestingly in this
study, Emp mRNA was detected in all the groups,
whereas the Emp protein was only detectable in bone
marrow mononuclear cells in HSCT group (Figure 2C).
These results suggested that Emp might be a potential
marker for bone marrow hematopoietic evaluation.
EPO, a kind of hormone preventing erythroid progeni-
tors’ apoptosis [22], had been widely used in clinics
[22-24]. Erythroblastic islands were barely found in bone
marrow smears before EPO therapy and were dramatic-
ally increased after EPO treatment (Table 2, Figure 3A).
Meanwhile, Emp protein level was significantly increased
in mononuclear cells from bone marrow in patients re-
ceiving EPO treatment (Figure 3B). The data indicate thatEmp protein expression could have a close correlation
with hematopoietic island formation in bone marrow.
Taken together, our findings provide that Emp protein
expression in bone marrow has a close relation with
hematopoietic island formation, which might be a poten-
tial marker for hematopoietic evaluation in clinic. Thus,
our findings suggest that erythobalst island formation is
likely an essential feature of erythropoiesis after HSCT.
Future studies will be required to assess if Emp levels
directly correlate with functional erthropoiesis in this
model.
Conclusions
The Emp expression correlates with erythroblastic island
formation and has an important function for bone mar-
row hematopoiesis. Based on our data, we suggest that
the Emp is a potential biomarker for hematopoietic
evaluation of HSCT patients.
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